Patents by Inventor Brice Stenne

Brice Stenne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR
    Publication number: 20230151006
    Abstract: Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
    Type: Application
    Filed: October 14, 2022
    Publication date: May 18, 2023
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Afton HISCOX, Akinola SOYODE-JOHNSON, Brice STENNE, Christa CHROVIAN, Christine GELIN, Andrew SAMANT, Michael A. LETAVIC, Curt DVORAK
  • Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators
    Patent number: 11618750
    Abstract: Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: April 4, 2023
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Afton Hiscox, Akinola Soyode-Johnson, Brice Stenne, Christa Chrovian, Christine Gelin, Andrew Samant, Michael A. Letavic, Curt Dvorak
  • SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
    Publication number: 20230045960
    Abstract: Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
    Type: Application
    Filed: September 12, 2022
    Publication date: February 16, 2023
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Afton HISCOX, Brice STENNE, Christa CHROVIAN, Christine GELIN, Andrew SAMANT, Michael A. LETAVIC, Curt DVORAK
  • Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators
    Patent number: 11530210
    Abstract: Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: December 20, 2022
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Afton Hiscox, Brice Stenne, Christa Chrovian, Christine Gelin, Andrew Samant, Michael A. Letavic, Curt Dvorak
  • SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
    Publication number: 20220324860
    Abstract: Substituted pyrazolo[4,3-b]pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
    Type: Application
    Filed: June 12, 2020
    Publication date: October 13, 2022
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Afton HISCOX, Brice STENNE, Christine GELIN, Andrew SAMANT, Jessica WALL, Michael A. LETAVIC, Curt DVORAK
  • Pyridine carbamates and their use as GLUN2B receptor modulators
    Patent number: 11447503
    Abstract: Pyridine carbamates, pharmaceutical compositions containing pyridine carbamates, and uses of the pyridine carbamates and pharmaceutical compositions for modulating GluN2B receptors and for treating diseases, disorders, and medical conditions mediated by GluN2B receptor activity.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: September 20, 2022
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Christine Gelin, Heather Coate, Brice Stenne, Curt Dvorak
  • SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
    Publication number: 20220274984
    Abstract: Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
    Type: Application
    Filed: February 9, 2022
    Publication date: September 1, 2022
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Afton HISCOX, Brice STENNE, Christa CHROVIAN, Christine GELIN, Andrew SAMANT, Michael A. LETAVIC, Curt DVORAK
  • Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators
    Patent number: 11161846
    Abstract: Substituted pyrazolo[4,3-b]pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: November 2, 2021
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Afton Hiscox, Brice Stenne, Christine Gelin, Andrew Samant, Jessica Wall, Michael A. Letavic, Curt Dvorak
  • SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
    Publication number: 20210017169
    Abstract: Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
    Type: Application
    Filed: June 12, 2020
    Publication date: January 21, 2021
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Afton HISCOX, Brice STENNE, Christa CHROVIAN, Christine GELIN, Andrew SAMANT, Michael A. LETAVIC, Curt DVORAK
  • SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
    Publication number: 20210017168
    Abstract: Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
    Type: Application
    Filed: June 12, 2020
    Publication date: January 21, 2021
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Afton HISCOX, Akinola SOYODE-JOHNSON, Brice STENNE, Christa CHROVIAN, Christine GELIN, Andrew SAMANT, Michael A. LETAVIC, Curt DVORAK
  • SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
    Publication number: 20200392130
    Abstract: Substituted pyrazolo[4,3-b]pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
    Type: Application
    Filed: June 12, 2020
    Publication date: December 17, 2020
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Afton HISCOX, Brice STENNE, Christine GELIN, Andrew SAMANT, Jessica WALL, Michael A. LETAVIC, Curt DVORAK
  • PYRIDINE CARBAMATES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
    Publication number: 20200392154
    Abstract: Pyridine carbamates, pharmaceutical compositions containing pyridine carbamates, and uses of the pyridine carbamates and pharmaceutical compositions for modulating GluN2B receptors and for treating diseases, disorders, and medical conditions mediated by GluN2B receptor activity.
    Type: Application
    Filed: June 12, 2020
    Publication date: December 17, 2020
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Christine GELIN, Heather COATE, Brice STENNE, Curt DVORAK
  • Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
    Patent number: 10766880
    Abstract: Substituted 1,2,3-triazoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
    Type: Grant
    Filed: December 31, 2018
    Date of Patent: September 8, 2020
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Gang Chen, Christa C. Chrovian, Heather R. Coate, Curt A. Dvorak, Christine F. Gelin, Afton Hiscox, Michael A. Letavic, Jason C. Rech, Akinola Soyode-Johnson, Brice Stenne, Jessica L. Wall, Wei Zhang
  • SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS
    Publication number: 20190135791
    Abstract: Substituted 1,2,3-triazoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
    Type: Application
    Filed: December 31, 2018
    Publication date: May 9, 2019
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Gang Chen, Christa C. Chrovian, Heather R. Coate, Curt A. Dvorak, Christine F. Gelin, Afton Hiscox, Michael A. Letavic, Jason C. Rech, Akinola Soyode-Johnson, Brice Stenne, Jessica L. Wall, Wei Zhang
  • Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
    Patent number: 10233173
    Abstract: Substituted 1,2,3-triazoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: March 19, 2019
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Gang Chen, Christa C Chrovian, Heather R. Coate, Curt A. Dvorak, Christine F. Gelin, Afton Hiscox, Michael A. Letavic, Jason C. Rech, Akinola Soyode-Johnson, Brice Stenne, Jessica L. Wall, Wei Zhang
  • SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS
    Publication number: 20180334451
    Abstract: Substituted 1,2,3-triazoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
    Type: Application
    Filed: July 26, 2018
    Publication date: November 22, 2018
    Inventors: Gang Chen, Christa C. Chrovian, Heather R. Coate, Curt A. Dvorak, Christine F. Gelin, Afton Hiscox, Michael A. Letavic, Jason C. Rech, Akinola Soyode-Johnson, Brice Stenne, Jessica L. Wall, Wei Zhang
  • Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
    Patent number: 10071988
    Abstract: Substituted 1,2,3-triazoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: September 11, 2018
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Gang Chen, Christa C. Chrovian, Heather R. Coate, Curt A. Dvorak, Christine F. Gelin, Afton Hiscox, Michael A. Letavic, Jason C. Rech, Akinola Soyode-Johnson, Brice Stenne, Jessica L. Wall, Wei Zhang
  • SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS
    Publication number: 20170226089
    Abstract: Substituted 1,2,3-triazoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
    Type: Application
    Filed: February 9, 2017
    Publication date: August 10, 2017
    Inventors: Gang Chen, Christa C. Chrovian, Heather R. Coate, Curt A. Dvorak, Christine F. Gelin, Afton Hiscox, Michael A. Letavic, Jason C. Rech, Akinola Soyode-Johnson, Brice Stenne, Jessica L. Wall, Wei Zhang